Amaç: Hiperhidroz (HH), ekrin ter bezlerinin hiperaktif çalışması sonucu deri yüzeyine vücudun normal fizyolojik ihtiyacından daha fazla miktarda ter salgılanması ile karakterize bir hastalıktır. Hipertiroidisi olan hastaların en önemli deri bulgularından biri HH'dur. Klinik pratikte primer HH tanısı koyduğumuz hastaların birçoğunda tiroid hormon düzeyleri referans değerler arasında, ancak üst limite yakın çıkmaktadır. Bu sebeple bu çalışmada, primer HH'lu hastaların tiroid hormon düzeyleri kontrol grubu ile karşılaştırılarak anlamlı bir farklılık olup olmadığının araştırılması amaçlanmıştır. Gereç ve Yöntemler: Çalışmada primer HH tanısı konulan 168 hasta ile kontrol grubu olarak yaş ve cinsiyet açısından benzer 121 sağlıklı birey yer aldı. HH hastaları ile kontrol grubu tiroid stimüle edici hormon (TSH), serbest triiyodotironin (ST3), serbest tiroksin (ST4) düzeyleri bakımından karşılaştırıldı. Bulgular: Çalışmaya dâhil edilen HH hastalarının %41,7 (70)'si kadın, %58,3 (98)'ü erkek; kontrol grubunun %44,6 (54)'sı kadın, %55,4 (67)'ü erkek idi. HH hastaları ile kontrol grubu karşılaştırıldığında HH grubunda ST3, ST4 düzeyleri anlamlı derecede daha yüksek iken, TSH düzeyleri bakımından hasta ve kontrol grubu arasında anlamlı bir fark bulunmadı. Hasta ve kontrol grubu cinsiyetlere göre alt gruba ayrılıp değerlendirildi. HH'lu erkek hastalarda kontrol grubu erkeklere göre sadece ST3 anlamlı derecede yüksek iken, HH'lu kadın hastalarda ST3 ve ST4 düzeyleri kontrol grubundaki kadınlara göre anlamlı derecede yüksek bulundu. Sonuç: Bu çalışmada ST3 ve ST4 hormonları HH hastalığı ile ilişkilendirilmiştir. Bu konuda yapılacak yeni çalışmalarla desteklendiği takdirde primer HH hastalarında tiroid hormonlarının referans değerlerinin alt sınırına yakın tutulması bir tedavi seçeneği olarak düşünülebilmektedir.
Anahtar Kelimeler: Hiperhidroz; hipertiroidizm; terleme; triiyodotironin; tiroksin
Objective:Hyperhidrosis (HH) is a disease characterized by the secretion of sweat into the skin surface in a greater amount than the normal physiological need of the body as a result of hyperactive study of eccrine sweat glands. One of the most important skin findings of patients with hyperthyroidism is HH. Thyroid hormone levels in most of the patients diagnosed as primary HH in clinical practice are within the reference values but close to the upper limit. Therefore, in this study, thyroid hormone levels of patients with primary HH were compared with the control group to determine whether there was a significant difference. Material and Methods: The study included 168 patients with primary HH and 121 age and sex-matched healthy control. Thyroid stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) levels were compared between HH patients and control group. Results: Of the HH patients included in the study, 41.7% (70) were female and 58.3% (98) were male. Of the patients in the control group, 44.6% (54) were female and 55.4% (67) were male. When HH patients and control groups were compared, the levels of FT3 and FT4 were significantly higher in the HH group, but there was no significant difference between the patient and control groups in terms of TSH levels. The patient and control groups were divided into subgroups according to gender and evaluated. While only FT3 was significantly higher in male patients with HH than in control group, FT3 and FT4 levels were significantly higher in female patients with HH than in the control group. Conclusion: In this study, FT3 and FT4 hormones were associated with HH. If supported by new studies on this subject, in primary HH patients keeping the thyroid hormones close to the lower limit may be considered as a treatment option.
Keywords: Hyperhidrosis; hyperthyroidism; sweating; triiodothyronine; thyroxine
- Leung AK, Chan PY, Choi MC. Hyperhidrosis. Int J Dermatol. 1999;38(8):561-7. [Crossref] [PubMed]
- Connolly M, de Berker D. Management of primary hyperhidrosis: a summary of the different treatment modalities. Am J Clin Dermatol. 2003;4(10):681-97. [Crossref] [PubMed]
- Gee S, Yamauchi PS. Nonsurgical management of hyperhidrosis. Thorac Surg Clin. 2008;18(2):141-55. [Crossref] [PubMed]
- Lenefsky M, Rice ZP. Hyperhidrosis and its impact on those living with it. Am J Manag Care. 2018;24(23 Suppl):S491-5.
- Adar R, Kurchin A, Zweig A, Mozes M. Palmar hyperhidrosis and its surgical management: a report of 100 cases. Ann Surg. 1977;186(1): 34-41. [Crossref] [PubMed] [PMC]
- Hasimoto EN, Cataneo DC, Reis TAD, Cataneo AJM. Hyperhidrosis: prevalence and impact on quality of life. J Bras Pneumol. 2018;44(4):292-8. [Crossref] [PubMed] [PMC]
- Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743-9. [Crossref] [PubMed] [PMC]
- Fujimoto T. Pathophysiology and treatment of hyperhidrosis. Curr Probl Dermatol. 2016;51: 86-93. [Crossref] [PubMed]
- Ohshima Y, Tamada Y. Classification of systemic and localized sweating disorders. Curr Probl Dermatol. 2016;51:7-10. [Crossref] [PubMed]
- Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients' daily life and quality of life: a qualitative investigation. Health Qual Life Outcomes. 2017;15(1):121. [Crossref] [PubMed] [PMC]
- Shayesteh A, Janlert U, Nylander E. Hyperhidrosis-sweating sites matter: quality of life in primary hyperhidrosis according to the sweating sites measured by SF-36. Dermatology. 2017;233(6):441-5. [Crossref] [PubMed]
- Goldsmith LA. Disorders of the eccrine sweat gland. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, eds. Dermatology in General Medicine. 5th ed. New York, NY: McGraw-Hill; 1999. p.800-9.
- Champion RH. Disorders of sweat glands. In: Champion RH, Burton JL, Burns DA, Breatnach SM, eds. Textbook of Dermatology. 6th ed. Oxford: Blackwell Science; 1998. p.1985-2002.
- Bülbül Başkan E, Sarıcaoğlu H. [Current approaches to hyperhidrosis therapy]. Turkiye Klinikleri J Cosmetol. 2003;4(4):165-72.
- Önder M, Aksoy G. [Hyperhidrosis]. Türkderm. 2011;45(1):2-9. [Crossref]
- Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders II. Disorder of sweat gland function. J Am Acad Dermatol. 1989;20(5 Pt 1):713-26. [Crossref]
- Özcan D, Güleç TA. [Hyperhidrosis and its treatment]. Turkiye Klinikleri J Dermatol. 2005;15(2):96-104.
- Takir M, Özlü E, Köstek O, Türkoğlu Z, Mutlu HH, Uzunçakmak TK, et al. Skin findings in autoimmune and nonautoimmune thyroid disease with respect to thyroid functional status and healthy controls. Turk J Med Sci. 2017;47(3):764-70. [Crossref] [PubMed]
- Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev. 1983;4(4):378-88. [Crossref] [PubMed]
- Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol. 2003;4(5):315-31. [Crossref] [PubMed]
- Rustin MH. Dermatology. Postgrad Med J. 1990;66(781):894-905. [Crossref] [PubMed] [PMC]
- Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders. Transl Pediatr. 2017;6(4):300-12. [Crossref] [PubMed] [PMC]
- Akbaş A, Kilinç F. Investigation on aetiological factors in patients with hyperhidrosis. Cutan Ocul Toxicol. 2018;37(4):344-9. [Crossref] [PubMed]
- Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2): 274-86. [Crossref] [PubMed]
- Baskan EB, Günay IT. [Structure and function of eccrine glands pathophysiology of hyperhidrosis]. Turkiye Klinikleri J Cosm Dermatol-Special Topics. 2011;4(1):1-7.
- Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8): 908-23. [Crossref] [PubMed]
- Sammons JE, Khachemoune A. Axillary hyperhidrosis: a focused review. J Dermatolog Treat. 2017; 28(7):582-90. [Crossref] [PubMed]
- Haider A, Solish N. Focal hyperhidrosis: diagnosis and management. CMAJ 2005;172(1): 69-75. [Crossref] [PubMed] [PMC]
- Shayesteh A, Janlert U, Brulin C, Boman J, Nylander E. Prevalence and characteristics of hyperhidrosis in Sweden: across-sectional study in the general population. Dermatology. 2016;232(5):586-91. [Crossref] [PubMed]
- Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperidrosis: results from a national survey. J Am Acad Dermatol. 2004;51(2):241-8. [Crossref] [PubMed]
- Lear W, Kessler E, Solish N, Glaser DA. An epidemiological study of hyperhidrosis. Dermatol Surg. 2007;33(1 Spec No.):S69-75. [Crossref] [PubMed]
- Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology. 2013;227(1):10-3. [Crossref] [PubMed]
- Lima SO, Aragão JF, Machado Neto J, Almeida KB, Menezes LM, Santana VR. Research of primary hyperhidrosis in students of medicine of the state of Sergipe, Brazil. An Bras Dermatol. 2015;90(5):661-5. [Crossref] [PubMed] [PMC]
.: Process List